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ess: takabata@med.id.Summary Although it has been reported that chronic obstructive pulmonary
disease (COPD) is frequently associated with systemic immune disturbances,
negative impact of these disturbances on the increased prevalence of acute
respiratory tract infections (aRTIs) has remained unclear. We evaluated circulating
levels of interferon-g (IFN-g), soluble interleukin-2 receptor (sIL-2R), neopterin, and
soluble intercellular adhesion molecule-1 (sICAM-1) in 35 clinically stable patients
with COPD and in 22 age-matched healthy controls, since these molecules are
considered to reflect the in vivo status of systemic cell-mediated immunity (CMI). We
found that circulating levels of sIL-2R (1.5271.25 vs. 0.9770.48 ng/ml; Po0:05),
neopterin (7.2374.24 vs. 4.9571.52 nmol/l; Po0:05), and sICAM-1 (6657302 vs.
3287164 ng/ml; Po0:0001), but not IFN-g (7.5574.72 vs. 6.6571.13 pg/ml; P=NS)
were significantly higher in patients with COPD than in the controls. Importantly,
follow-up study for 12 months demonstrated that patients in subgroup with
relatively higher circulating levels of sIL-2R (2.2071.44 ng/ml, n ¼ 18) had
significantly higher risk of developing aRTIs (P ¼ 0:0204) than those in subgroup
with relatively lower circulating levels of sIL-2R (0.8070.23 ng/ml, n ¼ 17). These
results may suggest that impaired systemic CMI observed in COPD patients is
associated with the increased susceptibility to aRTIs in these patients.
& 2004 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Chronic obstructive pulmonary disease (COPD)
denotes a group of diseases that affect the
respiratory tract, characterized by chronic airflow
limitation, dyspnea, and hypoxemia, which is
largely irreversible.1 COPD patients are also char-
acterized by periodic exacerbations, some of which
are caused by pulmonary infections such as
pneumonia.2 Epidemiological studies have impli-
cated recurrence of acute respiratory tract infec-
tions (aRTIs), with bacterial or viral etiology, as one
of the major factors associated with the progres-
sion of chronic airway obstruction, and conse-
quently leading to the unfavorable outcome in
these patients.3,4
Previous studies have preferably focused the
predisposing conditions to pulmonary infection in
patients with COPD on the disruption of the local
defense system seen in these patients, such as
impaired mucociliary clearance and/or altered
composition of the epithelial lining fluid observed
in the damaged airway tract.5,6 However, it has
been shown that COPD patients are frequently
associated with systemic immune disturbances.
Abnormalities in the distribution and in the func-
tion of T-lymphocyte7–9 and natural killer (NK)
cell10–12 subsets in patients with COPD have been
described in the literature. For example, periph-
eral blood NK cell cytotoxic activity has been
reported to be significantly depressed in stable
patients with COPD compared with levels in healthy
volunteers.13 In addition, alterations in effector
functions and cytokine production by peripheral
blood mononuclear cells and polymorphonuclear
cells have been reported in patients with
COPD.11,12,14–19 For example, phagocytic activity
of peripheral monocytes/macrophages and poly-
morphonuclear cells have also been reported to be
significantly depressed in stable patients with COPD
compared with levels in healthy volunteers.13
These findings are considered to imply a status of
compromised cell-mediated immunity (CMI) in
these patients. Although these COPD-associated
systemic immunoalterations may play a role in the
increased susceptibility to infectious complica-
tions, clinically negative impact of these impair-
ments on the increased prevalence of aRTIs in
patients with COPD has remained unclear.
In this study, we measured the circulating levels
of interferon-g (IFN-g), soluble interleukin-2
receptor (sIL-2R), neopterin, and soluble intercel-
lular adhesion molecule-1 (sICAM-1) in patients
with COPD, in order to assess the present state
of systemic CMI in these patients. In vitro
studies revealed that human monocyte/macrophage produce neopterin upon stimulation
with IFN-g released from activated T-lympho-
cyte.20,21 Activated T-lymphocyte also produces
large amounts of sIL-2R and sICAM-1.22–24
Since activation of the T-lymphocyte/macrophage
axis is one of the primary mechanisms of
cell-mediated immune response, the productions
of these molecules are considered to be closely
associated with the status of the CMI.20–24 These
in vitro data are consistent with the results
of numerous in vivo studies demonstrating that
some of these molecules, especially sIL-2R and
neopterin, serve as sensitive markers monitoring
disease activity in clinical disorders such as chronic
infections, autoimmune diseases, malignancies,
and allograft rejection, in which the activation of
the CMI plays a pivotal role in the pathophysiolo-
gical features.20–23
Elevated sIL-2R and neopterin levels and
progressive increases of these molecules in
accordance with the disease severity have been
reported in human immunodeficiency virus-in-
fected patients.20–23 In autoimmune diseases, such
as rheumatoid arthritis, significantly elevated
sIL-2R and neopterin levels and its correlation with
the extent and activity of the disease have
been reported by several investigators.20–23 In
neoplastic diseases, especially hematologic malig-
nancies, elevated sIL-2R and neopterin
levels reflect tumor burden, and levels of these
molecules correlate with the stage of the disease
and with the effectiveness of therapeutic interven-
tion. Also, high levels of these molecules
are significantly associated with poor prog-
nosis.20–23 In allograft rejection, serum levels of
sIL-2R and neopterin, earlier (mean 2–4 days) than
is possible using other conventional techniques,
have been shown to be significantly elevated during
acute rejection episodes, in comparison with
patients with other complications or stable en-
graftment.20–23 Overall, measurements of these
molecules in various clinical settings with disor-
dered status of systemic CMI are superior to other
conventional diagnostic procedures because of its
fast, accurate, and sensitive qualities for detecting
CMI-related pathophysiological changes.
Against these backgrounds, we investigated the
questions of: (i) whether circulating levels of these
molecules are significantly changed and/or related
to the clinical indices in patients with COPD, and
(ii) whether circulating levels of these molecules
are associated with the likelihood of the aRTIs
events in patients with COPD in follow-up study.
Elucidating these two questions may provide
clinical insights into the pathophysiology of sys-
temic immunoalterations in patients with COPD.
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Study population
Thirty-five male patients with COPD were diag-
nosed according to the criteria established by the
American Thoracic Society.25 Their irreversible
chronic airflow obstruction was confirmed by
spirogram. The present COPD patients were clini-
cally stable at the time of this study. Patients with
severe concomitant disease making follow-up study
difficult or unlikely and those who had been
prescribed medications affecting the immune sys-
tem (i.e., immunosupressants or systemic corticos-
teroids for more than 2 weeks in the last month)
were excluded, as well as those who had an episode
of acute exacerbation treated with antibiotics
within the previous month.
All patients had no clinical or laboratory evi-
dence of disease affecting the immune system such
as neoplasm, autoimmune, or infectious disease.
Patients with abnormal liver or renal function tests
were not included in this study. All patients were
ex-smokers.
Twenty-two age-matched healthy male volun-
teers were studied as control subjects. These
control subjects had normal physical examinations,
peripheral blood counts, and blood chemistries,
and showed no symptoms or signs of infection at
the time of study. None of these subjects were
taking any medications. All these subjects were ex-
or never-smokers.
The study protocol was approved by the local
ethical committee of Yamagata University School of
Medicine, and the written informed consent was
obtained from all subjects before participating in
this study.Clinical study
Prior to the follow-up study, complete medical
histories were recorded. Physical examination,
routine biochemistry, pulmonary function tests
(FVC, FEV1.0), chest X-ray, and blood gas were also
performed. FVC and FEV1.0 were measured with
standard spirometric techniques (CHESTAC-25 part
II EX; Chest Corp., Tokyo, Japan).26,27 The highest
value from at least three spirometric maneuvers
was used. FVC and FEV1.0 were expressed as
percentage of predicted values (%FVC and
%FEV1.0, respectively) according to the prediction
equations of the Japanese Society of Chest Dis-
eases.28 Arterial blood gas tensions were analyzed
with the subject breathing room air while in thesitting position (280 Blood Gas System; Ciba Corning
Diagnostics Corp., Medfield, MA).Determination of serum neopterin and
plasma IFN-c, sIL-2R, and sICAM-1 levels
Blood samples were collected from the cubital vein
in subjects after an overnight fast when the clinical
studies were performed. Both serum and plasma
were separated from blood cells by centrifugation
at 1000 g for 5min. All samples were stored at
70 1C until analyzed.
Serum neopterin (IBL Corp., Hamburg, Ger-
many), plasma IFN-g and sIL-2R (Quantikine; R&D
Systems, Minneapolis, MN), and plasma sICAM-1
(Immunotech Corp., Marseilles, France) concentra-
tions were measured in duplicate using commer-
cially available enzyme-linked immunosorbent
assay (ELISA) kits in accordance with the manufac-
turer’s instructions. Standards of defined concen-
trations of recombinant molecule were run in each
assay, allowing the construction of a calibration
curve from which unknown values of samples were
calculated. The lower limit of detection of serum
neopterin and plasma IFN-g, sIL-2R, and sICAM-1
were 0.5 nmol/l and 3.0, 6.0, and 100 pg/ml,
respectively.Follow-up procedures
The patients were required to specify monthly any
possible infections they had had, as well as
supplemental medication, consumption of antibio-
tics (type, amount, and duration of therapy), and
general symptoms prospectively for 12 months
after the clinical study and blood sampling. At
each hospital visit, a study physician evaluated
each patient who was suspected of having an
exacerbation. Clinically, an episode was considered
to represent an aRTI when the patient met the
following three conditions: (i) change in sputum
(color, texture, or quantity), (ii) occurrence of at
least one additional symptom among increased
shortness of breath or cough, or presence of fever,
and (iii) evidence of the nontrivial nature of the
episode (as determined by either an unscheduled
hospital visit and/or use of antibiotics). In addition,
the evidence of exacerbation was confirmed by
clear laboratory finding(s) such as increased C-
reactive protein level or increased peripheral blood
leukocyte count, and radiographic finding(s) such as
pneumonia. All this work was blind to the nature of
the laboratory data examined at the beginning of
this study.
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Because the normality hypothesis was not always
fulfilled for most of the variables, statistical analysis
was performed with Mann–Whitney’s U-test for
nonparametric data to analyze the differences
between the two groups. The relations between
continuous variables were evaluated with Spearman’s
rank correlation technique. Kaplan–Meier curves and
log-rank tests were used to compare the risk of
developing aRTIs events during the follow-up period
between the two groups. Results were expressed as
mean7SD. Significance was determined at the 5%
level. Statistical analysis was done with the Statview
Statistical Package (Statview Inc., Berkeley, CA).Results
Characteristic of the study population
Clinical characteristics of both the COPD patients
and the healthy controls are summarized in Table 1.
The patients were associated with airflow limita-
tion and decreased arterial blood O2 pressure
(PaO2) compared with the control subjects.Table 1 Study population.
COPD patients (n=35)
Age (yr) 70.276.5
FVC (% predicted) 80.3720.6
FEV1 (% predicted) 45.2721.6
FEV1/FVC (%) 42.0710.9
Arterial PO2 (Torr) 65.3710.2
Arterial PCO2 (Torr) 46.277.8
Values presented are mean7SD.
*Mann–Whitney U-test. NS: not significant.
Table 2 Concentrations of serum neopterin, plasma IF
healthy subjects.
COPD patients (n=35)
INF-g (pg/ml) 7.5574.72
sIL-2R (ng/ml) 1.5271.25
Neopterin (nmol/l) 7.2374.24
sICAM-1 (ng/ml) 6657302
Values presented are mean7SD.
*Mann–Whitney U-test. NS: not significant.Circulating levels of IFN-c, sIL-2R, neopterin,
and sICAM-1 in COPD patients
We measured serum neopterin and plasma IFN-g,
sIL-2R, and sICAM-1 levels in both groups (Table 2).
Although circulating levels of IFN-g did not show
significant difference between the two groups,
levels of sIL-2R, neopterin, and sICAM-1 were
significantly higher in patients with COPD than in
the control subjects. In addition, as shown in Fig. 1,
there were significant correlations between circu-
lating levels of sIL-2R and neopterin (r ¼ 0:437;
Po0:05; Fig. 1B), and levels of sIL-2R and sICAM-1
(r ¼ 0:404; Po0:05; Fig. 1C) in patients with COPD.
These relationships were not observed in the
control group. Circulating levels of IFN-g did not
show any significant correlation with levels of sIL-
2R (Fig. 1A), neopterin, and sICAM-1 in both groups.
We next examined the relationship between
these markers and clinical indices in patients with
COPD. There was significant inverse correlation
between circulating levels of sIL-2R and PaO2
(r ¼ 0:381; Po0:05). There were no significant
correlations between circulating levels of IFN-g,
neopterin, and sICAM-1 and clinical indices in
patients with COPD.Healthy subjects (n=22) P-value*
69.775.6 NS
109.2714.8 o0:0001
123.8719.3 o0:0001
79.575.6 o0:0001
87.079.8 o0:0001
42.873.0 NS
N-g, sIL-2R, and sICAM-1 in patients with COPD and
Healthy subjects (n=22) P-value*
6.6571.13 NS
0.9770.48 o0:05
4.9571.52 o0:05
3287164 o0:0001
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Figure 1 Correlations between circulating levels of sIL-
2R and IFN-g (A), neopterin (B), and sICAM-1 (C) in
patients with COPD. The relations between continuous
variables (r and P values) were evaluated with Spear-
man’s rank correlation technique.
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All of the present COPD patients were followed in
prospect of the occurrence of one or more episodes
of aRTIs for 12 months after the clinical study and
blood sampling. No patients were dropped out or
eliminated except for death. During the follow-up
period, a total of eight patients were hospitalizedand one of these patients was hospitalized two
times, due to aRTIs. All episodes of aRTIs required
hospitalization for treatment. Sputum samples of
the five of these patients with aRTIs yielded a
positive culture of a possible pathogen: Haemophi-
lus influenzae as the sole pathogen for two
patients, Streptococcus pneumoniae as the sole
pathogen for one patient, Pseudomonas aeruginosa
as the sole pathogen for one patient, and Haemo-
philus parainfluenzae combined with Pseudomonas
aeruginosa as the pathogens for one patient. The
other samples yielded nonspecific culture growth.
Two patients died of severe pneumonia.
In order to assess whether circulating levels of
sIL-2R, neopterin, and sICAM-1 are associated with
the likelihood of the aRTIs events in patients with
COPD in follow-up study, we first divided present
COPD patients into two subgroups (upper half: n ¼
18; Group A; lower half: n ¼ 17; Group B) according
to circulating levels of these molecules, respec-
tively. This is because we had a small sample size,
and because a balance was required for the
statistical analysis. We next counted the number
of the patients with and without the incidence of
one or more aRTIs in both subgroups during the
follow-up period. At the end of the follow-up
period, we observed a significant difference
(P ¼ 0:0204) in the number of patients with aRTIs
between the subgroups divided by the levels of sIL-
2R, but not by the levels of neopterin or sICAM-1
(Fig. 2A–C, respectively). Significantly higher risk of
developing aRTIs was observed in Group A (sIL-2R;
2.20 (7.61–1.23) ng/ml, seven of the 18 patients
were affected) than in Group B (sIL-2R; 0.80
(1.22–0.35) ng/ml, one of the 17 patients was
affected) in this subgroup analysis (Fig. 2A). Similar
subgroup analysis according to the levels of IFN-g
did not show significant difference in the risk of
developing aRTIs in these patients. Although many
effects of smoking on the immune system are
transient, there are no significant differences in the
duration of time after smoke-quitting between the
subgroups according to the levels of each molecule
measured in this study (data not shown).Discussion
In the present study, we showed that circulating
levels of sIL-2R, neopterin, and sICAM-1, but not
IFN-g, were significantly elevated in clinically
stable patients with COPD, compared with the
control subjects. In addition, follow-up study for 12
months after the measurements of these molecules
demonstrated that patients in subgroup with
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Figure 2 Kaplan–Meier curves and log-lank tests to
compare the risk of developing aRTIs events in the
subgroup analysis according to the levels of sIL-2R (A),
neopterin (B), and sICAM-1 (C), during the follow-up
period for 12 months. Solid lines represent the subgroups
with relatively higher circulating levels of each molecules
(upper half: n ¼ 18; Group A). Broken lines represent the
subgroups with relatively lower circulating levels of each
molecules (lower half: n ¼ 17; Group B). y represents the
patients who died of severe pneumonia.
N. Takabatake et al.490relatively higher circulating levels of sIL-2R had
significantly higher risk of developing aRTIs during
the period than those in subgroup with relatively
lower circulating levels of sIL-2R. Since these
molecules, especially sIL-2R and neopterin, are
considered to reflect the in vivo status of CMI, our
results may suggest that disordered status of
systemic CMI observed in COPD patients, at least
in part, contributes to the increased prevalence of
aRTIs in these patients.Various tests are currently used to evaluate the
status of CMI in a variety of conditions. However,
many of these are in vitro tests which are too
complicated for routine clinical use. Proliferation
assays or phenotypic characterization of cell
populations are restricted to specialized labora-
tories. In addition, in vitro tests do not necessarily
reflect the in vivo situation. An alternative
approach is to quantify specific products of cells
of the immune system which are biologically stable
and are sufficiently detectable in body fluids. In
these aspects, we measured circulating levels of
sIL-2R and neopterin along with other molecules
since these two molecules have been shown to be
sensitive and reliable indicator of cellular immune
activation providing direct information in the in
vivo situation of the CMI which is not easily
obtained by other techniques.
In the present study, we could neither demon-
strate a significant difference in the levels of
circulating IFN-g between the two groups, nor
significant interrelationships between the levels
of IFN-g and those of other molecules in patients
with COPD (Table 2 and Fig. 1A). These results may
be attributable to the fact that endogenously
formed IFN-g is less sensitively detectable than
concentrations of IFN-g-inducible molecules such as
neopterin, since IFN-g is subject to fast degradation
and is able to bind to soluble or cell bound
receptors in systemic circulation.20,21 It is assumed
therefore that the actual biological effective
concentration of IFN-g may indicate deviations to
the free measurable concentrations obtained in
this study.
In the follow-up study, we could find a significant
difference in the number of patients with aRTIs
between the subgroups according to the levels of
sIL-2R (Fig. 2A, P ¼ 0:0204), but not to the levels of
neopterin or sICAM-1 (Fig. 2B and C, respectively),
although we found significant correlations between
circulating levels of sIL-2R and neopterin, and levels
of sIL-2R and sICAM-1 in patients with COPD (Fig. 1B
and C, respectively). These differences in the level
of statistical significance are likely due to the weak
statistical power with the small sample size. More-
over, sICAM-1 is known to be released not only from
the T-lymphocytes, but also from the endothelial
and epithelial cells.24,29,30 This may have acted as a
potential confounding factor to the levels of
circulating sICAM-1 as an indicator of the status of
the systemic CMI in our COPD patients.
Physiological significance of elevated circulating
levels of sIL-2R and neopterin in the present COPD
patients is difficult to explain. According to immuno-
surveillance theory, cellular immune activation usual-
ly produces a beneficial effect to the host; however,
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sIL-2R were associated with higher risk of developing
aRTIs during the follow-up period. This seemingly
incongruous behavior of the immune system may
imply that activation of the CMI with elevated sIL-2R
or neopterin concentrations in patients with COPD
coexist with functional defects of immune effector
mechanisms. sIL-2R and neopterin release seems to
occur as a result of a cellular immune response and is
not directly associated with microbicidal or virucidal
activity of activated T-lymphocytes or macro-
phages.20–23 Elevations of these two molecules were
detected in a variety of diseases in which activation
of the CMI is known to play a key role, such as
allograft rejections, viral and certain microbial
infections, trauma, and autoimmune disease.20–23 In
all these diseases, CMI-related T-cell responses by
antigenic stimulation in vitro are typically impaired,
possibly by the in vivo presence of cytokines due to
persistent immune activation.31 We previously re-
ported the activation of the tumor necrosis factor-a
system and its relation to the chronic hypoxemia in
patients with COPD.32 In addition, similar relationship
was observed between circulating levels of sIL-2R and
PaO2 in the present COPD patients. Taken together, it
might be that elevated levels of these two molecules
in patients with COPD are not associated with the
activation of the systemic CMI beneficial for immu-
nosurveillance, but rather with the compromised CMI
responsible for the increased susceptibility to infec-
tious microbes.
In this study, there was an inverse correlation
between circulating sIL-2R levels and arterial PaO2
levels in patients with COPD. Also, the subgroup
with relatively higher levels of sIL-2R was at higher
risk to experience an aRTIs than those with lower
sIL-2R levels (Fig. 2A). Chronic hypoxemia is a good
measure of disease severity and it is well known
that exacerbations are more common and severe in
severe patients with COPD. It would seem therefore
that the difference in risk for an aRTIs between the
subgroups with higher and lower sIL-2R levels
coincides with a difference in disease severity.
However, the correlation between sIL-2R levels and
PaO2 levels in COPD patients is relatively weak
(r ¼ 0:381; Po0:05). In addition, there is no
significant difference at risk to develop aRTIs
between the subgroups with relatively lower and
higher levels of PaO2 in the follow-up study (data
not shown). These results suggest that impaired
CMI, at least in part, contributes to the increased
susceptibility to the respiratory infections in
patients with COPD, independently of disease
severity.
Dentener et al.33 recently suggested an imbal-
ance in systemic levels of pro- and anti-inflamma-tory mediators in patients with stable COPD, and
correction of this imbalance during the treatment
of exacerbations. Although we did not investigate
the behavior of these CMI-related molecules during
the treatment of aRTIs in this study, inappropriate
activation of systemic CMI, demonstrated in this
study, may contribute to a shift of the balance of
pro- and anti-inflammatory mediators toward the
pro-inflammatory predominance in patients with
stable COPD. Recent studies have reported a
relation between bacterial colonization of patients
with stable COPD and persistent local inflammation
as measured in sputum and BAL fluid.34,35 The
presence of lower airway bacterial colonization was
also reported to be related to exacerbation
frequency.36 Further studies are required to clarify
the relationship between lower respiratory tract
infection and inappropriate activation of systemic
CMI.
In summary, we evaluated circulating levels of
IFN-g, sIL-2R, neopterin, and sICAM-1 in clinically
stable patients with COPD and in age-matched
healthy controls. We demonstrated that circulating
levels of sIL-2R, neopterin, and sICAM-1, but not
IFN-g, were significantly higher in patients with
COPD than in the healthy controls. We also showed
that patients with higher circulating levels of sIL-2R
had significantly increased risk of developing aRTIs
than those with lower circulating levels of sIL-2R
during the follow-up period for 12 months. The
results of this study may suggest that impaired
systemic cell-mediated immune response in pa-
tients with COPD is associated with the increased
susceptibility to pulmonary infections in these
patients. We believe that it is of great clinical
and scientific interest to attempt to clarify the
potential role of CMI for the increased suscept-
ibility to respiratory infections commonly seen in
patients with COPD.Acknowledgments
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